Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.

14 This approach has been endorsed by recent initiatives of the National Institutes of Health 15 and the National Institute of Mental Health 16 and has been an increasing trend in industry as well. 17 To date, a number of existing compounds have been examined for possible repurposing in schizophrenia, including anti-inflammatory drugs, anti-epileptic drugs and several hormones, 18 based on pathophysiologic hypotheses with varying levels of empirical support.

also in 63,971 other papers